- ROUNDTABLE: Pharmacy’s future in sync with technology
- CVS Caremark to stop selling tobacco in all store locations
- Coalition of healthcare industry stakeholders address best practices regarding controlled substances
- Study from NCPA sheds new light on med synchronization programs
- Senate passes Drug Quality and Security Act
PRINCETON, N.J. — Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, today reported that it has made an initial shipment of its first honey-based over-the-counter product to a leading U.S.-based pharmacy chain. This private-label dressing is based on the Medihoney HCS dressing, which is an ideal dressing for dry to lightly exuding wounds including minor burns, cuts and abrasions. The dressing is expected to be on the shelves in more than 4,000 stores by the end of September. This OTC dressing is expected to add approximately $1.2 million to Derma Sciences’ traditional wound care sales in the second half of 2013.
“The development of an OTC honey-based dressing is an important achievement for Derma Sciences and is indicative of our ability to modify our advanced wound care products to the consumer market,” said Edward J. Quilty, Derma Sciences chairman and chief executive officer. “We are thrilled that this large pharmacy chain has recognized the quality of our products and are excited to offer this innovative dressing, our first honey-based OTC dressing, to the broader market.”
As part of the private-label supply agreement, Derma Sciences will be working with the pharmacy chain to encourage adoption and utilization. The company will launch a similar dressing into the professional market during the fourth quarter in order to create initial awareness and demand within the hospital setting, and then educate patients and caregivers to the product’s availability within the retail pharmacy setting.
Like this story? Find us on Facebook for more insight, analysis and the latest in drug store news. Join the conversation.